171 related articles for article (PubMed ID: 26208852)
21. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
Uckun FM; Pitt J; Qazi S
Expert Rev Anticancer Ther; 2011 Jan; 11(1):37-48. PubMed ID: 21070101
[TBL] [Abstract][Full Text] [Related]
22. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
Loh ML; Zhang J; Harvey RC; Roberts K; Payne-Turner D; Kang H; Wu G; Chen X; Becksfort J; Edmonson M; Buetow KH; Carroll WL; Chen IM; Wood B; Borowitz MJ; Devidas M; Gerhard DS; Bowman P; Larsen E; Winick N; Raetz E; Smith M; Downing JR; Willman CL; Mullighan CG; Hunger SP
Blood; 2013 Jan; 121(3):485-8. PubMed ID: 23212523
[TBL] [Abstract][Full Text] [Related]
24. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
[TBL] [Abstract][Full Text] [Related]
25. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
[TBL] [Abstract][Full Text] [Related]
26. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
[TBL] [Abstract][Full Text] [Related]
27. The molecular genetic makeup of acute lymphoblastic leukemia.
Mullighan CG
Hematology Am Soc Hematol Educ Program; 2012; 2012():389-96. PubMed ID: 23233609
[TBL] [Abstract][Full Text] [Related]
28. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
[TBL] [Abstract][Full Text] [Related]
29. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.
Vicente C; Schwab C; Broux M; Geerdens E; Degryse S; Demeyer S; Lahortiga I; Elliott A; Chilton L; La Starza R; Mecucci C; Vandenberghe P; Goulden N; Vora A; Moorman AV; Soulier J; Harrison CJ; Clappier E; Cools J
Haematologica; 2015 Oct; 100(10):1301-10. PubMed ID: 26206799
[TBL] [Abstract][Full Text] [Related]
30. Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.
Gordon GM; Lambert QT; Daniel KG; Reuther GW
Biochem J; 2010 Dec; 432(2):255-65. PubMed ID: 20868368
[TBL] [Abstract][Full Text] [Related]
31. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia.
Blink M; Buitenkamp TD; van den Heuvel-Eibrink MM; Danen-van Oorschot AA; de Haas V; Reinhardt D; Klusmann JH; Zimmermann M; Devidas M; Carroll AJ; Basso G; Pession A; Hasle H; Pieters R; Rabin KR; Izraeli S; Zwaan CM
Leukemia; 2011 Aug; 25(8):1365-8. PubMed ID: 21537335
[No Abstract] [Full Text] [Related]
32. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD
Leukemia; 2018 Mar; 32(3):788-800. PubMed ID: 28852199
[TBL] [Abstract][Full Text] [Related]
33. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.
Tasian SK; Loh ML
Crit Rev Oncog; 2011; 16(1-2):13-24. PubMed ID: 22150304
[TBL] [Abstract][Full Text] [Related]
34. Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains.
Canté-Barrett K; Uitdehaag JC; Meijerink JP
Haematologica; 2016 May; 101(5):e189-91. PubMed ID: 26819051
[No Abstract] [Full Text] [Related]
35. Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B.
Batista CR; Lim M; Laramée AS; Abu-Sardanah F; Xu LS; Hossain R; Bell GI; Hess DA; DeKoter RP
Blood Adv; 2018 Nov; 2(21):2798-2810. PubMed ID: 30355579
[TBL] [Abstract][Full Text] [Related]
36. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.
Witthuhn BA; Williams MD; Kerawalla H; Uckun FM
Leuk Lymphoma; 1999 Jan; 32(3-4):289-97. PubMed ID: 10037026
[TBL] [Abstract][Full Text] [Related]
37. Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.
Huang TC; Cutler J; Bharne S; Zhong J; Weinstock D; Tyner J; Gojo I; Civin C; Pandey A
Leuk Lymphoma; 2015 May; 56(5):1524-7. PubMed ID: 25213184
[No Abstract] [Full Text] [Related]
38. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.
Shochat C; Tal N; Bandapalli OR; Palmi C; Ganmore I; te Kronnie G; Cario G; Cazzaniga G; Kulozik AE; Stanulla M; Schrappe M; Biondi A; Basso G; Bercovich D; Muckenthaler MU; Izraeli S
J Exp Med; 2011 May; 208(5):901-8. PubMed ID: 21536738
[TBL] [Abstract][Full Text] [Related]
39. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
40. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia.
Wang Q; Qiu H; Jiang H; Wu L; Dong S; Pan J; Wang W; Ping N; Xia J; Sun A; Wu D; Xue Y; Drexler HG; Macleod RA; Chen S
Haematologica; 2011 Dec; 96(12):1808-14. PubMed ID: 21880637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
